Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 24, 2024

Acer Among Top 5% Scoring Companies in S&P Global Corporate Sustainability Assessment • An adventure every day after school: Boys and Girls Clubs of Central Arizona • Swisscom Accelerates Sustainability and Innovation with Genesys Cloud • iHeartMedia and Deep Blue Sports + Entertainment Launch Women’s Sports Audio Network – The First-Ever Audio Platform • Tech Innovator Purba Majumder Recognized as One of North America's Top 100 Women Leaders in 2024 • Experience Senior Living Celebrates the Opening of the new Independent Living community at The Gallery at Cape Coral • Curio Digital Therapeutics Inc. Announces the U.S. Food and Drug Administration (FDA) Clearance of MamaLift Plus™, the Fir • New Study in Colorado Reveals Alarming Rates of Colorado Teens Missing School • FPT Cooperates with USAID to Promote Clean Energy Deployment, Reduce Greenhouse Gas Emissions, and Accelerate Net Zero Transitio • Empire State Realty Trust Publishes 2023 Sustainability Report with Major Achievements, Key Goals, and Transparent Metrics • Brookdale Announces Date of First Quarter 2024 Earnings Release and Conference Call • Coeur Publishes 2023 ESG Report • Rocket Lab Successfully Deploys Satellites ~500km Apart to Separate Orbits For KAIST and NASA • Woodside Energy Group Ltd Annual General Meeting Address by Chair Richard Goyder and CEO Meg O'Neill • Minister Sudds highlights budget investments in support of Indigenous Reconciliation • LG Energy Solution to Take Firm Stance Against Patent Infringers • Minister of Employment, Workforce Development and Official Languages highlights budget investments in support of Indigenous reco • Loop Media Discloses Communication from NYSE American • Dr. Anthony Fletcher Installed as President of the Association of Black Cardiologists • Voto Latino Announces Honorees for 16th Annual Our Voices Celebration

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , December 07 /Businesswire/ - Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company’s Board of Directors granted four employees nonqualified stock options to purchase 65,500 shares of its common stock with an exercise price of $7.07 per share, which is equal to the closing price of Kezar’s common stock on December 5, 2022, the grant date of the awards. The stock options were granted as an inducement award material to the individuals entering into employment with Kezar, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options will vest over a four-year period, with 25% of each option vesting on the first anniversary of the employee’s start date, and 1/48th of the total shares vesting monthly thereafter, subject to continued employment on each vesting date. The options are subject to the terms and conditions of Kezar’s 2022 Inducement Plan and the stock option agreement covering the grants.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing novel treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor has completed a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com.